| 0.57 -0.119 (-17.26%) | 07-20 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 0.82 |
1-year : | 0.89 |
| Resists | First : | 0.7 |
Second : | 0.76 |
| Pivot price | 0.68 |
|||
| Supports | First : | 0.61 |
Second : | 0.5 |
| MAs | MA(5) : | 0.66 |
MA(20) : | 0.68 |
| MA(100) : | 0.79 |
MA(250) : | 1.22 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 40.2 |
D(3) : | 50.1 |
| RSI | RSI(14): 37.9 |
|||
| 52-week | High : | 2.83 | Low : | 0.49 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CTOR ] has closed below the lower bollinger band by 14.7%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ CTOR ] is to continue within current trading range. It is unclear right now based on current values. 55.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 14 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.68 - 0.68 | 0.68 - 0.69 |
| Low: | 0.6 - 0.61 | 0.61 - 0.61 |
| Close: | 0.6 - 0.61 | 0.61 - 0.62 |
Citius Oncology, Inc. concentrates on advancing innovative, targeted therapeutic solutions for various cancer types. A key aspect of its pipeline includes the development of LYMPHIR, an investigational orphan drug intended to treat adults battling cutaneous T-cell lymphoma that has either relapsed or is unresponsive to existing therapies. The firm's main offices are situated in New York, New York. Citius Oncology, Inc. functions as a division of its parent company, Citius Pharmaceuticals, Inc.
Wed, 15 Jul 2026
Citius Oncology (Nasdaq: CTOR) sets $18M stock deal at $1.09 to back LYMPHIR launch - Stock Titan
Wed, 15 Jul 2026
Citius Oncology (CTOR) Registration filing Summary - Quartr
Wed, 15 Jul 2026
Citius Oncology (CTOR) Registration filing Summary - Quartr
Fri, 26 Jun 2026
Price to sales forward of Citius Oncology, Inc. – NASDAQ:CTOR - TradingView
Fri, 26 Jun 2026
CTOR Forecast — Price Target — Prediction for 2027 - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - General
|
|
| Shares Out | 0 (M) |
| Shares Float | 93 (M) |
| Held by Insiders | 1.772e+007 (%) |
| Held by Institutions | 77.5 (%) |
| Shares Short | 632 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | 0 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 716.1 % |
| Return on Equity (ttm) | -28.4 % |
| Qtrly Rev. Growth | 5.61e+006 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -34.46 |
| EBITDA (p.s.) | 1.29023e+006 |
| Qtrly Earnings Growth | -0.5 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -17 (M) |
| PE Ratio | 0 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.02 |
| Price to Cash Flow | 5.58 |
| Dividend | 0 |
| Forward Dividend | 453350 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|